🇺🇸 FDA
Patent

US 9556237

Antiviral rift valley fever virus peptides and methods of use

granted A61KA61K38/00A61K38/10

Quick answer

US patent 9556237 (Antiviral rift valley fever virus peptides and methods of use) held by The United States of America, as represented by the Secretary of the Army, on behalf of the U.S. Army Medical Research Institute of Infectious Diseases expires Mon Jan 26 2037 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
The United States of America, as represented by the Secretary of the Army, on behalf of the U.S. Army Medical Research Institute of Infectious Diseases
Grant date
Tue Jan 31 2017 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Jan 26 2037 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
8
CPC classes
A61K, A61K38/00, A61K38/10, A61K38/162, A61K39/12